This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AAV1FS344, AAV1-follistatin gene therapy, rAAV1.CMV.huFollistatin344
Description: AAV1-FS344 is an adeno-associated virus (AAV) gene therapy delivering a muscle-specific transgene of the protein, follistatin. Follistatin inhibits the activity of myostatin, a protein that impedes muscle differentiation and growth.
Additional information available to subscribers only: